Home » Archive

Articles tagged with: biotech

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy

Posted by sandiegobiotech February 3rd, 2012 .
No Comments
—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says

Posted by sandiegobiotech February 1st, 2012 .
No Comments
Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug

Posted by sandiegobiotech January 31st, 2012 .
No Comments
[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic

Posted by sandiegobiotech January 31st, 2012 .
No Comments
Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer (NYSE: PFE) turned an old-school antifungal...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Four Themes to Watch in Personalized Medicine

Posted by sandiegobiotech January 30th, 2012 .
No Comments
Good morning from Mountain View, CA, and from the close of the 2012 Personalized Medicine World Conference, which brought together thought leaders of business, government, healthcare-delivery,...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Never Back Smug: A Lesson for Life Sciences From Newt Gingrich

Posted by sandiegobiotech January 30th, 2012 .
No Comments
Newt Gingrich comes across on TV as someone who radiates smugness. It’s that sense that he’s not just confident in his own abilities, but extremely satisfied with his talents and his utter...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Amylin, Alkermes Win FDA Approval of Once-Weekly Diabetes Drug

Posted by sandiegobiotech January 27th, 2012 .
No Comments
[Updated: 3:47 pm] Amylin Pharmaceuticals and Alkermes have gone to the FDA twice before to seek approval of their new diabetes drug, and been turned back, but now the persistence has paid off. The...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

2012 Venture Outlook: Some Bright Spots and Some Gloom

Posted by sandiegobiotech January 27th, 2012 .
No Comments
It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital....

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Why Biogen Idec Got Out of the Corporate VC Business

Posted by sandiegobiotech January 27th, 2012 .
No Comments
Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French. The concept...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Roche Makes $5.7B Hostile Takeover Bid for Illumina

Posted by sandiegobiotech January 25th, 2012 .
No Comments
San Diego-based Illumina, the market leading maker of DNA sequencing instruments, has just made it through a rough year, and now it may be entering its final chapters as an independent company....

[[Click headline to continue reading.]] More...